Emotra AB (“Emotra” or “the Company”) has decided to postpone the publication of its third-quarter report. 201007 - Emotra - PM - Emotra, postpones publication of 3q report
Our efforts to plan and recruit clinics for our study to document the connection between hyporeactivity and depression relapse continues. 200929 - Emotra - PM - Emotra, update on research
Emotra will be holding a presentation at Aktiespararna’s Shareholder day. To watch the whole presentation, please click the link below: 2000908 - Emotra- PM - Presentation at Aktiespararna's shareholder day
The Board and CEO of Emotra AB (publ) hereby present the interim report for the first six months of 2020. 200825 Interim report Jan- June 2020
Emotra has signed a collaboration agreement for clinical studies with the General Psychiatry clinic at Örebro University hospital
Emotra has lately been focusing on the indication area depression relapse. Our goal is to start a clinical study in 2020. Emotra’s agreement with the General Psychiatry clinic (Allmänpsykiatriska kliniken) at Örebro University Hospital is another important step...
The Annual General Meeting of EMOTRA AB (publ) was held today, June 3, 2020. The resolutions, summarised below, were all adopted with the necessary majority. 200603 - Emotra- PM - Communique from AGM
The Board and CEO of Emotra AB hereby present the interim report for the first three months of 2020. 200529 Interim report Jan- March 2020
Since the autumn of 2017, Emotra has been involved in a dispute with an Italian consultancy, ABC Form Srl. Semplificata (“ABC”), for work mainly performed by professor Marco Sarchiapone from 2014 to 2017. 200528 - Emotra - PM - Claim form served concerning...
The use of AI, or machine learning, for EDOR test has been identified as an important technical development area for our method. 200526 - Emotra - PM - Emotra is collaborating with RISE for EDOR test
Many companies in the so-called life science sector have been affected by the ongoing pandemic, and Emotra is no exception. 200507 - Emotra - PM - Effects of Covid-19 on Emotra's operations